Monitor for future data readouts from these investigator-initiated trials, which could support regulatory discussions for label expansion. Increased real-world use in AYA and adult populations may drive off-label adoption and commercial growth.
Price Chart
Executive Summary
Fennec Pharmaceuticals announced the initiation of an investigator-sponsored Phase I/II study at the University of Arizona Cancer Center evaluating PEDMARK® in adolescent and adult patients with solid tumors receiving cisplatin chemotherapy. This adds to recent institutional studies at Tampa General Hospital and City of Hope, expanding real-world validation of PEDMARK® beyond its current pediatric indication. The company continues to build evidence for potential label expansion into adult populations.
Key Facts
- University of Arizona Cancer Center has initiated a Phase I/II trial of PEDMARK® in AYA and adult patients with head and neck and testicular cancers receiving cisplatin.
- This is the third institution-led study announced in recent months, following Tampa General Hospital and City of Hope.
- PEDMARK® is currently FDA-approved only for pediatric patients, but has a 2A NCCN recommendation for use in AYA patients.
- The study will assess efficacy in reducing hearing impairment and systemic elimination of unbound cisplatin.
Financial Impact
No immediate financial impact disclosed; potential long-term revenue expansion if label is broadened to adults.
Risk Factors
- Regulatory approval for adult indications is uncertain and may require additional clinical data.
- Potential safety or efficacy issues in adult populations not seen in pediatric trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3268978 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | SC 13G/A | $10.27 | awaiting T+60 | — | $10.15 (−1.17%) |
Aug 31, 2026 8w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.15 (−15.63%) |
Aug 31, 2026 8w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.15 (−15.63%) |
Aug 11, 2026 11w ago | Press Release | $12.78 | awaiting T+60 | — | $10.15 (−20.58%) |
Jun 15, 2026 19w ago | Press Release | $9.19 $11.65 | ▲ +26.77% | ▲ +25.77% | $10.15 (+10.45%) |
May 22, 2026 22w ago | 8-K | $9.89 $11.87 | ▲ +20.02% | ▲ +17.30% | $10.15 (+2.63%) |
May 18, 2026 23w ago | 8-K | $9.76 $12.06 | ▲ +23.57% | ▲ +17.28% | $10.15 (+4.00%) |
May 14, 2026 23w ago | Press Release | $9.24 $10.94 | ▲ +18.40% | ▲ +14.81% | $10.15 (+9.85%) |
May 7, 2026 24w ago | Press Release | $6.90 $9.59 | ▲ +38.99% | ▲ +35.15% | $10.15 (+47.10%) |
Apr 28, 2026 25w ago | 8-K | $6.26 $9.99 | ▲ +59.58% | ▲ +55.47% | $10.15 (+62.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers